

PRESS RELEASE

DICOT

The Subscription Period for Dicot's Rights Issue Begins and The Company Invites to Investment Events

Today on September 3, 2019, the subscription period for the rights issue in Dicot AB (publ) ("Dicot" or the "Company") commences and continues until September 17, 2019. The Company hereby invites shareholders and investors to participate in investment meetings at Mangold's offices in Malmö and Stockholm.

Today is the first day of the subscription period for Dicot's rights issue. The Company intends to use the proceeds from the rights issue to continue preclinical testing and prepare for a Phase-1 study. More information about the rights issue can be found on the Company's website, www.dicot.se, and on Mangold's website, www.mangold.se. It is possible to subscribe for shares on Mangold's website using the electronic identification solution BankID.

Please see below for further information about each investment meeting and how to register.

Mangold, Stockholm

Date: September 11, 2019

Time: 11:30

Location: Engelbrektsplan 2, Stockholm

Register at: dicot@mangold.se

Mangold, Malmö

Date: September 12, 2019

Time: 11:45

Location: Elite Hotel Esplanade, Malmö

Register at: anmalan@mangold.se

For further information, please contact:

Julie Silber, CFO and Director of Investor Relations, Dicot

Tel: +46 79 348 62 77

E-mail: julie.silber@dicot.se

www.dicot.se

About Dicot AB

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.